Join
Live feed
·
PRReleasevia Quantisnow
I-MAB logo

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

ByQuantisnow·Wall Street's wire, on your screen.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IMAB (I-MAB) and more on Quantisnow.